Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study
Dermatitis® · 01.11.2026 · 37 (6) · 992-998
DOI: 10.1089/derm.2025.0118 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Dermatitis®, online erschienen am 15.05.2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
An anti-interleukin-13 antibody lebrikizumab is effective for atopic dermatitis (AD). However, predictive factors for responders to lebrikizumab are unknown in real-world practice.
Objective
To identify predictive factors for early and late responders to lebrikizumab treatment for AD.
Methods
A prospective study was conducted with 112 Japanese patients with AD who received lebrikizumab between May 2024 and February 2025. Early responders were defined as patients who achieved investigator’s global assessment (IGA) 0/1 at week 12, and late responders were defined as those who did not achieve IGA 0/1 at week 12 but achieved IGA 0/1 at week 24. We compared patients’ background factors and baseline clinical or laboratory indexes between responders and poor responders.
Results
Early responders showed lower baseline eczema area and severity index (EASI), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) while late responders showed lower baseline immunoglobulin E (IgE), eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), PLR, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) compared with respective poor responders.
Conclusions
Patients with AD with lower baseline EASI, TARC, LDH, and PLR may predict early responses, while those with lower baseline IgE, ELR, NLR, MLR, PLR, SII, and SIRI may predict late responses to lebrikizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino
Zitieren
APA
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study. Dermatitis®, 37(6), 992-998. https://doi.org/10.1089/derm.2025.0118
Vancouver
Hagino T, Saeki H, Fujimoto E, Kanda N. Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study. Dermatitis®. 2026;37(6):992-998. doi:10.1089/derm.2025.0118
BibTeX
@article{Hagino2026,
author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study},
journal = {Dermatitis®},
year = {2026},
volume = {37},
number = {6},
pages = {992--998},
doi = {10.1089/derm.2025.0118}
}
EUVIMED